V2 sact_regimen
781,388 rows · 12 columns
| ENCORE_PATIENT_ID | MERGED_REGIMEN_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | BENCHMARK_GROUP | LINK_NUMBER |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 240001628 | 240001628 | 1.6 | 57.6 | 03 | null | 2018-11-09 | DA | 02 | N | RITUXIMAB | 100519114 |
| 240001630 | 240001630 | null | null | null | null | 2018-07-11 | Azacitidine | null | null | CLADRIBINE | 101099883 |
| 240001632 | 240001632 | null | null | null | null | 2016-11-08 | CHOP R | null | null | NOT MATCHED | 100566501 |
| 240001633 | 240001633 | 1.58 | 74.6 | Palliative (P) | null | 2018-12-26 | Cladribine (subcut) 5 days | 02 | N | DA | 101582921 |
| 240001636 | 240001636 | 1.66 | 59 | Curative (C) | null | 2017-04-29 | Hydroxycarbamide | N | N | TRIAL | 100426160 |
| 240001639 | 240001639 | 1.73 | 63 | Curative (C) | null | 2018-10-23 | null | N | N | CYCLOPHOSPHAMIDE + DOXORUBICIN + RITUXIMAB + VINCRISTINE | 100452248 |
| 240001640 | 240001640 | 1.71 | 61.1 | Curative (C) | 2016-04-04 | 2016-04-23 | null | 02 | N | AML16 TRIAL | 101441526 |
| 240001648 | 240001648 | 1.67 | 51.3 | Curative (C) | null | 2019-10-19 | null | 02 | N | DOXORUBICIN | 100124320 |
| 240001653 | 240001653 | null | null | null | null | 2017-09-22 | null | null | null | AML18 TRIAL | 101659129 |
| 240001656 | 240001656 | 1.6 | 64.4 | 03 | null | 2018-07-01 | null | 2 | N | AZACITIDINE | 100307085 |
| 240001657 | 240001657 | null | null | null | null | 2018-08-24 | CHOP R - 21 days | null | null | CYCLOPHOSPHAMIDE + DOXORUBICIN + RITUXIMAB + VINCRISTINE | 100154361 |
| 240001659 | 240001659 | null | null | null | null | 2018-01-18 | null | null | null | CHOP R | 100079215 |
| 240001660 | 240001660 | 1.54 | 121 | 03 | null | 2016-05-06 | null | N | N | CHOP R | 100666230 |
| 240001669 | 240001669 | 1.7 | 69.5 | Curative (C) | null | 2019-03-24 | IMATINIB | 02 | N | CYTARABINE + DAUNORUBICIN | 101432013 |
| 240001675 | 240001675 | 1.9 | 58.65 | Curative (C) | 2021-06-28 | 2021-07-13 | AML 18 TRIAL | 02 | N | AML19 TRIAL | 101513654 |
| 240001676 | 240001676 | 1.84 | 113 | null | null | 2019-04-15 | FLAIR trial | 02 | N | IFOSFAMIDE | 100208933 |
| 240001678 | 240001678 | null | null | null | null | 2018-07-20 | ALL UKALL2011 IndB Std Dex (PegAsp) | null | null | AML19 TRIAL | 100725114 |
| 240001684 | 240001684 | 0 | 10.75 | 03 | null | 2016-06-05 | Trial Unspecified | 02 | N | AML19 TRIAL | 101570421 |
| 240001686 | 240001686 | null | 82.3 | Curative (C) | 2019-10-04 | 2019-10-06 | CHOP R | 02 | N | CYTARABINE + DAUNORUBICIN | 100808155 |
| 240001688 | 240001688 | 1.78 | 71 | 03 | 2017-05-01 | 2017-05-01 | null | 02 | N | HYDROXYCARBAMIDE | 100497019 |
| 240001690 | 240001690 | 1.54 | 90.1 | Curative (C) | null | 2020-01-30 | CHOP R | 02 | N | CYTARABINE | 101448940 |
| 240001694 | 240001694 | 1.86 | 90.8 | 03 | null | 2016-05-25 | BENDAMUSTINE + RITUXIMAB | N | N | CYTARABINE + DAUNORUBICIN + GEMTUZUMAB OZOGAMICIN | 100997278 |
| 240001703 | 240001703 | 1.72 | 50.8 | 03 | 2017-01-19 | 2017-01-24 | AML 18 TRIAL | 02 | N | FLAIR TRIAL | 100529386 |
| 240001721 | 240001721 | 1.8 | 88 | 03 | null | 2016-08-13 | RUXOLITINIB | 02 | N | CYCLOPHOSPHAMIDE + DOXORUBICIN + ETOPOSIDE + RITUXIMAB + VINCRISTINE | 100333093 |
| 240001723 | 240001723 | 0 | 84.9 | Curative (C) | null | 2018-04-27 | Azacitidine | 1 | N | AML18 TRIAL | 100653483 |
| 240001735 | 240001735 | 0 | 80.4 | Adjuvant (A) | 2017-03-27 | 2017-03-28 | null | 02 | N | BENDAMUSTINE + RITUXIMAB | 101766114 |
| 240001741 | 240001741 | 1.57 | 91.9 | Curative (C) | 2016-04-05 | 2016-04-07 | null | 01 | N | AZACITIDINE | 101419440 |
| 240001744 | 240001744 | null | null | null | 2019-12-06 | 2019-12-07 | CHLORAMBUCIL + OBINUTUZUMAB | 02 | null | CYCLOPHOSPHAMIDE + FLUDARABINE + RITUXIMAB | 100033560 |
| 240001745 | 240001745 | null | null | null | null | 2016-09-20 | CHOP R | null | null | CYCLOPHOSPHAMIDE + CYTARABINE + DOXORUBICIN + RITUXIMAB + VINCRISTINE | 100083166 |
| 240001746 | 240001746 | 1.62 | 110 | 03 | null | 2018-03-28 | AML MyeChild 01 IT Cyt | 02 | N | METHOTREXATE | 101363262 |
| 240001747 | 240001747 | 1.7 | 74.4 | Curative (C) | null | 2018-12-05 | CHOP R - 21 days | null | Y | CYCLOPHOSPHAMIDE + DOXORUBICIN + RITUXIMAB + VINCRISTINE | 100029842 |
| 240001754 | 240001754 | 1.83 | 60.2 | Curative (C) | 2016-04-27 | 2016-04-27 | null | 01 | N | CYCLOPHOSPHAMIDE + DOXORUBICIN + RITUXIMAB + VINCRISTINE | 100310231 |
| 240001757 | 240001757 | 1.58 | 101.6 | Palliative (P) | 2016-11-29 | 2016-12-03 | null | 02 | N | BENDAMUSTINE + RITUXIMAB | 101390699 |
| 240001759 | 240001759 | 1.78 | 105.8 | Curative (C) | 2012-11-16 | 2012-11-17 | CLADRIBINE | 02 | N | DA | 100389935 |
| 240001761 | 240001761 | 1.68 | 67.7 | Curative (C) | null | 2017-11-08 | Chlorambucil | N | null | AML18 TRIAL | 101837663 |
| 240001770 | 240001770 | 1.72 | 162.7 | Curative (C) | 2018-07-13 | 2018-07-13 | CHLORAMBUCIL + OBINUTUZUMAB | 02 | N | AML19 TRIAL | 101256613 |
| 240001771 | 240001771 | 1.8 | 73.2 | Curative (C) | 2017-08-05 | 2017-08-05 | Trial Unspecified | N | N | CYCLOPHOSPHAMIDE + CYTARABINE + DOXORUBICIN + METHOTREXATE + RITUXIMAB + VINCRISTINE | 101693311 |
| 240001773 | 240001773 | 1.57 | 57.4 | Curative (C) | null | 2018-12-15 | AML16 DA 3+10 | 02 | N | IBRUTINIB | 101208722 |
| 240001774 | 240001774 | null | null | null | null | 2019-09-10 | null | null | null | TRETINOIN | 101801193 |
| 240001784 | 240001784 | 1.79 | 72 | Curative (C) | null | 2019-11-23 | null | 02 | N | LIPOSOMAL DAUNORUBICIN + LIPOSOMAL CYTARABINE (VYXEOS) | 100887087 |
| 240001792 | 240001792 | 0 | 102 | Curative (C) | 2018-08-28 | 2018-08-28 | CHOP R | Y | N | HYDROXYCARBAMIDE | 101781351 |
| 240001794 | 240001794 | 1.56 | 117 | 03 | 2017-08-02 | 2017-08-03 | Bortezomib + CYCLOPHOSPHAMIDE + DOXORUBICIN + RITUXIMAB | null | N | CYCLOPHOSPHAMIDE + CYTARABINE + DOXORUBICIN + METHOTREXATE + RITUXIMAB + VINCRISTINE | 100748209 |
| 240001798 | 240001798 | 1.6 | 45.35 | Palliative (P) | null | 2019-07-01 | Bortezomib + Thalidomide +/- Dex | 02 | N | FCR | 100969561 |
| 240001800 | 240001800 | 1.57 | 79.5 | Curative (C) | null | 2016-06-20 | AML 19 TRIAL | N | N | CYCLOPHOSPHAMIDE + DOXORUBICIN + RITUXIMAB + VINCRISTINE | 101005204 |
| 240001818 | 240001818 | null | null | null | null | 2019-08-05 | CHOP R - 21 days | null | null | AZACITIDINE | 101189206 |
| 240001819 | 240001819 | 1.72 | 42 | Curative (C) | 2016-08-31 | 2016-08-31 | AML 18 TRIAL | 01 | null | ARSENIC TRIOXIDE + TRETINOIN | 101391358 |
| 240001831 | 240001831 | 1.59 | 87.7 | Curative (C) | null | 2019-06-28 | null | 02 | N | MATRIX LYMPHOMA TRIAL | 101059376 |
| 240001859 | 240001859 | 1.77 | 111.8 | Palliative (P) | null | 2019-02-11 | Methotrexate intrathecal | 02 | N | AZACITIDINE | 101038753 |
| 240001869 | 240001869 | 1.71 | 114 | Curative (C) | null | 2018-05-19 | CHOP R - 21 days | N | N | BEVACIZUMAB + CARBOPLATIN + PACLITAXEL | 101123947 |
| 240001870 | 240001870 | null | null | null | null | 2019-08-13 | CYCLOPHOSPHAMIDE + ETOPOSIDE + Procarbazine | null | null | TRIPLE INTRATHECAL | 100197703 |